✦ LIBER ✦

Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction

✍ Scribed by Schwenkglenks, M.; Toward, T. J.; Plent, S.; Szucs, T. D.; Blackman, D. J.; Baumbach, A.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Upstream Treatment of ST-Segment Elevati

✍ Dominique Joyal; Mark J. Eisenberg 📂 Article 📅 2011 🏛 Pulsus Group Inc 🌐 English ⚖ 341 KB

Administration of Glycoprotein IIb-IIIa

✍ Paul P. Dobesh; Jennifer B. Kasiar 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB

The use of glycoprotein IIb/IIIa inhibit

✍ Kevin R Campbell; E.Magnus Ohman; Warren Cantor; A.Michael Lincoff 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 297 KB

Head-to-head comparison of bivalirudin v

✍ Laurent Bonello; Axel de Labriolle; Probal Roy; Daniel H. Steinberg; Tina L. Pin 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 190 KB

Comparison of Bivalirudin Versus Bivalir

✍ Dinesh Kumar; George Dangas; Roxana Mehran; Ajay Kirtane; Michel Bertrand; Ramin 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 152 KB

AS-85: Clinical Benefits of Glycoprotein

✍ Doo Sun Sim; Youngkeun Ahn; Myung Ho Jeong; Young Jo Kim; Shung Chull Chae; Taek 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 83 KB